Fragment-based drug discovery

Same author

Correction to "Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective".

Journal of medicinal chemistry·2026

Same author

A practical method for determining the rate of covalent modification of fragments and leads.

Nature communications·2025

Same author

Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.

Molecular metabolism·2025

Same author

Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective.

Journal of medicinal chemistry·2025

Same author

Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation.

Structure (London, England : 1993)·2025

Same author

A case-matched controlled retrospective performance indexed analysis of Thoroughbred racehorses that underwent surgical repair of proximal phalanx and third meta-carpal/tarsal condylar fractures.

Equine veterinary journal·2025

Same journal

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Journal of medicinal chemistry·2026

Same journal

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Journal of medicinal chemistry·2026

Same journal

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

Journal of medicinal chemistry·2026

Same journal

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Journal of medicinal chemistry·2026

Same journal

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Journal of medicinal chemistry·2026

Same journal

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026

Related Experiment Videos

Fragment-based drug discovery

Related Concept Videos

Correction to "Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective".

A practical method for determining the rate of covalent modification of fragments and leads.

Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.

Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective.

Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation.

A case-matched controlled retrospective performance indexed analysis of Thoroughbred racehorses that underwent surgical repair of proximal phalanx and third meta-carpal/tarsal condylar fractures.

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Related Experiment Videos

Fragment-based drug discovery

Related Concept Videos

Related Articles

Correction to "Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective".

A practical method for determining the rate of covalent modification of fragments and leads.

Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.

Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective.

Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation.

A case-matched controlled retrospective performance indexed analysis of Thoroughbred racehorses that underwent surgical repair of proximal phalanx and third meta-carpal/tarsal condylar fractures.

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.